Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

XOMA 052 fails in Phase IIb diabetes study, but CEO looking on the bright side

This article was originally published in Scrip

Executive Summary

While he wasn't quite singing "Always look on the bright side of life," XOMA Chairman and CEO Steven B. Engle tried his best to convince investors during a 22 March evening conference call that all was not lost for XOMA 052 after it failed in a Phase IIb study to significantly reduce glycosylated hemoglobin (HbA1c) in patients with Type II diabetes.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012353

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel